Abstract:Background The chemokine CXCL14 has been reported to play an important role in the progression of many malignancies such as breast cancer and papillary thyroid carcinoma, but the role of CXCL14 in colorectal carcinoma (CRC) remains to be established. The purpose of this study was to investigate the expression pattern and significance of CXCL14 in CRC progression. Method 265 colorectal carcinoma specimens and 129 matched adjacent normal colorectal mucosa specimens were collected. Expression of CXCL14 in clinical samples was examined by immunostaining. The effect of CXCL14 on colorectal carcinoma cell proliferation was measured by MTT assay, BrdU incorporation assay and colony formation assay. The impact of CXCL14 on migration and invasion of colorectal carcinoma cells was determined by transwell assay and Matrigel invasion assay, respectively. Results CXCL14 expression was significantly up-regulated in tumor tissues compared with adjacent nontumorous mucosa tissues ( P < 0.001). Tumoral CXCL14 expression levels were significantly correlated with TNM (Tumor-node-metastasis) stage, histodifferentiation, and tumor size. In multivariate Cox regression analysis, high CXCL14 expression in tumor specimens (n = 91) from stage I/II patients was associated with increased risk for disease recurrence (risk ratio, 2.92; 95% CI, 1.15-7.40; P = 0.024). Elevated CXCL14 expression in tumor specimens (n = 135) from stage III/IV patients correlated with worse overall survival (risk ratio, 3.087; 95% CI, 1.866-5.107; P < 0.001). Functional studies demonstrated that enforced expression of CXCL14 in SW620 colorectal carcinoma cells resulted in more aggressive phenotypes. In contrast, knockdown of CXCL14 expression could mitigate the proliferative, migratory and invasive potential of HCT116 colorectal carcinoma cells. Conclusion Taken together, CXCL14 might be a potential novel prognostic factor to predict the disease recurrence and overall survival and could be a potential target of postoperative adjuvant therapy in CRC patients.

CXCL4 and Its Receptor in Colorectal Cancer

The expression of chemokine receptor CXCR4 in colorectal cancer and its clinical significance

Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer

CXCL4 and CXCL4L1 in cancer

CXCL12/CXCR4 and breast cancer

CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines.

Alteration of Cxcr7 Expression Mediated by Tlr4 Promotes Tumor Cell Proliferation and Migration in Human Colorectal Carcinoma

Chemokine CXCL14 is Associated with Prognosis in Patients with Colorectal Carcinoma after Curative Resection

Research progress about CXCR4 and tumor

CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

Role of chemokine receptor CXCR4/CXCL12 signaling pathway in hepatic metastasis of colorectal carcinoma

CCL3 Promotes Proliferation of Colorectal Cancer

CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

Roles of CXCL12/CXCR4 axis in tumor growth and metastasis and related mechanisms

Expression and Clinical Significance of the CXC Chemokine Receptor-4 (CXCR4) in Breast Cancer

The CXCL12 (SDF-1)/CXCR4 Chemokine Axis: Oncogenic Properties, Molecular Targeting, and Synthetic and Natural Product CXCR4 Inhibitors for Cancer Therapy.

Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy.

CCR4 promotes metastasis via ERK/NF-κB/MMP13 pathway and acts downstream of TNF-α in colorectal cancer.